PDF herunterladen
Horm Metab Res 2019; 51(08): 487-494
DOI: 10.1055/a-0958-2441
Review
© Georg Thieme Verlag KG Stuttgart · New York

Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes

Peili Wu   *
1   Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Weiheng Wen   *
1   Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Jitong Li   *
1   Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Jie Xu
1   Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Min Zhao
1   Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Hong Chen
1   Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Jia Sun
1   Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 25. September 2018

accepted 12. Juni 2019

Publikationsdatum:
13. August 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new kind of hypoglycemic drugs that improve glucose homeostasis by inhibiting renal glucose reabsorption. Recent studies have shown that SGLT2 inhibitors can also mediate body metabolism through regulation of adipokines level, but the effects of SGLT2 inhibitors on the concentration of adipokines (leptin and adiponectin) remains controversial. This meta-analysis was set out to evaluate the changes in circulating leptin and adiponectin levels in patients with type 2 diabetes mellitus (T2DM) receiving SGLT2 inhibitors therapy. Ten randomized controlled trials (RCTs), that evaluated the effects of SGLT2 inhibitors on blood leptin and adiponectin levels in patients with type 2 diabetes, were identified by performing a systematic search of Pubmed, Embase, Cochrane, and Web of science databases through July 2018. Data were calculated using a random-effects model and presented as standardized mean difference (SMD) and 95% confidence interval (CI). Compared with placebo, treatment with SGLT2 inhibitors contributed to a decreased circulating leptin levels (SMD −0.29, 95% CI −0.56, −0.03) and an increased circulating adiponectin levels (SMD 0.30, 95% CI 0.22, 0.38). SGLT2 inhibitor treatment was associated with decreased circulating leptin levels and increased circulating adiponectin levels, which might contribute to the beneficial effects of SGLT2 inhibitors on metabolic homeostasis.

Key words

hypoglycemic drugs - adipokines - type 2 diabetes mellitus

* Contributed equally to this work.


Supplementary Material

 

  • References

  • 1 Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: The last ten years. Cell 2012; 148: 1160-1171
    CrossrefPubMedGoogle Scholar
  • 2 Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol 2007; 2: 31-56
    CrossrefPubMedGoogle Scholar
  • 3 Zhang Y, Proenca R, Maffei M. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432
    CrossrefPubMedGoogle Scholar
  • 4 Farooqi IS, O'Rahilly S. 20 years of leptin: Human disorders of leptin action. J Endocrinol 2014; 223: T63-T70
    CrossrefPubMedGoogle Scholar
  • 5 Ouchi N, Parker JL, Lugus JJ. et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97
    CrossrefPubMedGoogle Scholar
  • 6 Roszkowska-Gancarz M, Kurylowicz A, Polosak J. et al. Functional polymorphisms of the leptin and leptin receptor genes are associated with longevity and with the risk of myocardial infarction and of type 2 diabetes mellitus. Endokrynol Pol 2014; 65: 11-16
    PubMedGoogle Scholar
  • 7 Romanowski M, Dziedziejko V, Maciejewska-Karlowska A. et al. Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus. Pharmacogenomics 2015; 16: 1243-1251
    CrossrefPubMedGoogle Scholar
  • 8 Perry RJ, Petersen KF, Shulman GI. Pleotropic effects of leptin to reverse insulin resistance and diabetic ketoacidosis. Diabetologia 2016; 59: 933-937
    CrossrefPubMedGoogle Scholar
  • 9 D'Souza AM, Neumann UH, Glavas MM. et al. The glucoregulatory actions of leptin. Mol Metab 2017; 6: 1052-1065
    CrossrefPubMedGoogle Scholar
  • 10 Yamauchi T, Kamon J, Ito Y. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769
    CrossrefPubMedGoogle Scholar
  • 11 Ouchi N, Kihara S, Arita Y. et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301
    CrossrefPubMedGoogle Scholar
  • 12 Bouassida A, Chamari K, Zaouali M. et al. Review on leptin and adiponectin responses and adaptations to acute and chronic exercise. Br J Sports Med 2010; 44: 620-630
    CrossrefPubMedGoogle Scholar
  • 13 Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin 2018; 39: 1176-1188
    CrossrefPubMedGoogle Scholar
  • 14 Wilding J, Fernando K, Milne N. et al. SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice. Diabetes Ther 2018; 9: 1757-1773
    CrossrefPubMedGoogle Scholar
  • 15 Jia X, Mehta PB, Ye Y. et al. SGLT2 inhibitors and cardiovascular outcomes: Current perspectives and future potentials. Curr Diab Rep 2018; 18: 63
    CrossrefPubMedGoogle Scholar
  • 16 Baptist G. The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors - Real-World Data. Eur Endocrinol 2018; 14: 17-23
    PubMedGoogle Scholar
  • 17 Fadini GP, Bonora BM, Zatti G. et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: A randomized placebo-controlled trial. Cardiovasc Diabetol 2017; 16: 42
    CrossrefPubMedGoogle Scholar
  • 18 Kusunoki M, Natsume Y, Miyata T. et al. Effects of Concomitant Administration of Sodium Glucose Co-transporter 2 Inhibitor with Insulin on Hemoglobin A1c, Body Mass Index and Serum Lipid Profile in Japanese Type 2 Diabetic Patients. Drug Res (Stuttg) 2018; 68: 669-672
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 19 Ito D, Shimizu S, Inoue K. et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial. Diabetes Care 2017; 40: 1364-1372
    CrossrefPubMedGoogle Scholar
  • 20 Seino Y, Sasaki T, Fukatsu A. et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245-1255
    CrossrefPubMedGoogle Scholar
  • 21 Ikeda S, Takano Y, Cynshi O. et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015; 17: 984-993
    CrossrefPubMedGoogle Scholar
  • 22 Bailey CJ, Iqbal N, T'Joen C. et al. Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012; 14: 951-959
    CrossrefPubMedGoogle Scholar
  • 23 Kashiwagi A, Kazuta K, Goto K. et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2015; 17: 304-308
    CrossrefPubMedGoogle Scholar
  • 24 Haneda M, Seino Y, Inagaki N. et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese Patients with type 2 diabetes mellitus. Clin Ther 2016; 38: 66-88.e20
    CrossrefPubMedGoogle Scholar
  • 25 Kashiwagi A, Takahashi H, Ishikawa H. et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: Results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab 2015; 17: 152-160
    CrossrefPubMedGoogle Scholar
  • 26 Ishihara H, Yamaguchi S, Nakao I. et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab 2016; 18: 1207-1216
    CrossrefPubMedGoogle Scholar
  • 27 Kaku K, Watada H, Iwamoto Y. et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014; 13: 65
    CrossrefPubMedGoogle Scholar
  • 28 Liao X, Wang X, Li H. et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Alpha2-Glycoprotein Levels in Patients with Type 2 Diabetes. Sci Rep 2016; 6: 32887
    CrossrefPubMedGoogle Scholar
  • 29 Ferrannini E, Muscelli E, Frascerra S. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508
    CrossrefPubMedGoogle Scholar
  • 30 Merovci A, Solis-Herrera C, Daniele G. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-514
    CrossrefPubMedGoogle Scholar
  • 31 Nicholson T, Church C, Baker DJ. et al. The role of adipokines in skeletal muscle inflammation and insulin sensitivity. J Inflamm (Lond) 2018; 15: 9
    CrossrefPubMedGoogle Scholar
  • 32 Tsuchida A, Yamauchi T, Ito Y. et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 30817-30822
    CrossrefPubMedGoogle Scholar
  • 33 Hopkins TA, Ouchi N, Shibata R. et al. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007; 74: 11-18
    CrossrefPubMedGoogle Scholar
  • 34 Fruebis J, Tsao TS, Javorschi S. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010
    CrossrefPubMedGoogle Scholar
  • 35 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
    CrossrefPubMedGoogle Scholar
  • 36 Gerstein HC, Miller ME, Byington RP. et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
    CrossrefPubMedGoogle Scholar
  • 37 Duckworth W, Abraira C, Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
    CrossrefPubMedGoogle Scholar
  • 38 Perez-Perez A, Vilarino-Garcia T, Fernandez-Riejos P. et al. Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev 2017; 35: 71-84
    CrossrefPubMedGoogle Scholar
  • 39 Liberale L, Bonaventura A, Vecchie A. et al. The role of adipocytokines in coronary atherosclerosis. Curr Atheroscler Rep 2017; 19: 10
    CrossrefPubMedGoogle Scholar
  • 40 Hoffmann A, Ebert T, Kloting N. et al. Leptin dose-dependently decreases atherosclerosis by attenuation of hypercholesterolemia and induction of adiponectin. Biochim Biophys Acta 2016; 1862: 113-120
    PubMedGoogle Scholar
  • 41 Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Endocr Metab Immune Disord Drug Targets 2012; 12: 118-131
    CrossrefPubMedGoogle Scholar
  • 42 Zhang H, Mo X, Hao Y. et al. Adiponectin levels and risk of coronary heart disease: A meta-analysis of prospective studies. Am J Med Sci 2013; 345: 455-461
    CrossrefPubMedGoogle Scholar
  • 43 Kobashi C, Urakaze M, Kishida M. et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005; 97: 1245-1252
    CrossrefPubMedGoogle Scholar
  • 44 Arita Y, Kihara S, Ouchi N. et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898
    CrossrefPubMedGoogle Scholar